Highlights PMD Device Solutions AB

Equities

PMDS

SE0021513645

Delayed Nasdaq Stockholm Other stock markets 05:27:31 2024-05-20 am EDT			5-day change	1st Jan Change
7.45 ^SEK	+1.36%		-9.70%	-34.90%

May. 02	PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology	CI
Apr. 11	PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology	May. 02	CI
PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	Apr. 10	CI
PMD Device Solutions to Purchase Coala-Life Group's US Unit	Apr. 09	MT
PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB.	Apr. 08	CI
PMD Device Solutions AB Begins Preparation for First German Hospital Pilot	Mar. 25	CI
PMD Device Solutions to Complete Reverse Stock Split; Shares Soar	Jan. 29	MT
Pmd Device Solutions AB completed the acquisition of Promore Pharma AB (OM:PROMO) in a reverse merger transaction.	Dec. 28	CI
Promore Pharma to Buy PMD Device Solutions via Reverse Acquisition; Stock Skyrockets	Nov. 29	MT
Pmd Device Solutions AB intends to acquire Promore Pharma AB (OM:PROMO) in a reverse merger transaction for approximately SEK 130 million.	Nov. 28	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Promore Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide	23-04-20	CI
Promore Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-28	CI
Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide	23-02-27	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Promore Pharma Provides an Update on the Phase II Clinical Trial with Ensereptide	22-11-01	CI
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Promore Pharma Up 15% After Receiving EU Patent For Drug	22-08-10	MT
Promore Pharma AB Receives A Granted Patent in the European Union for the Use of the Candidate Drug Ropocamptide (LL-37) for the Treatment of Chronic Wounds	22-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PMD Device Solutions AB

Equities

PMDS

SE0021513645

Highlights

Filters